Synageva BioPharma Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Document Sample
Synageva BioPharma Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile Powered By Docstoc
					                   Synageva BioPharma Corp. - Pharmaceuticals & Healthcare - Deals and
                                           Alliances Profile
       Reference Code: GDPH137372D                                                                                                           Publication Date: JUN 2013

      Company Overview                                                                                        Key Facts
      Synageva BioPharma Corp. (Synageva) is a biopharmaceutical company, based in
                                                                                                              Synageva BioPharma Corp., Pharmaceuticals &
      the US. It discovers, develops and delivers medicines for patients with rare disease
                                                                                                              Healthcare, Key Facts
      and unmet medical need. The company’s programs include SBC-102, SBC-103,
      SBC-104, SBC-105 and SBC-106. Its SBC-102 is an enzyme replacement therapy                               Web Address                      www.synageva.com
      for lysosomal acid lipase deficiency, a lysosomal storage disorder. The company’s
                                                                                                               Revenue (US$ million)                           NA
      SBC-102 contains glycan structures that are specifically recognized and internalized
      by specific receptors into key target cells. It received orphan drug designations in                     Number of Employees                             NA
      both the US and EU in 2010 for SBC-102 for LAL deficiency, and human dosing in                          GlobalData
      clinical trials is underway.

      Financial Deals Landscape
        Synageva BioPharma Corp., Pharmaceuticals & Healthcare,                           Synageva BioPharma Corp., Pharmaceuticals & Healthcare,
        Deals by Type, 2007 to YTD 2013                                                   Deals By Year, 2007 to YTD 2013


                                                                                                                                                3        3
                                                                                                          3


                                                                                           No. of Deals
                                                                                                                                   2
                                                                                                          2

                                                                                                                                                                   1
                                                                                                          1

                                                                                                                0        0               0
                                                                                                          0
                                                                                                               2007     2008    2009    2010   2011     2012   YTD
                                                                                                                                                               2013


                                                                                          Note: Deals include all announced pharmaceuticals & healthcare deals
         Note: Deals include all announced pharmaceuticals & healthcare deals from
                                                                                          from 2006 onwards, GlobalData
         2006 onwards, GlobalData


         Synageva BioPharma Corp., Pharmaceuticals & Healthcare,                          Synageva BioPharma Corp., Pharmaceuticals & Healthcare,
         Deals By Region, 2007 to YTD 2013                                                Deals By Therapy Area, 2007 to YTD 2013

                         10     9                                                                         8
          No. of Deals




                                                                                                                    6
                                                                                           No. of Deals




                         8
                                                                                                          6                    5
                         6                                                                                                               4
                         4                                                                                4                                         3
                                         2                                                                                                                     2
                         2                         0        0        0                                    2
                         0
                              North     Asia-    Europe   Middle   South                                  0
                              Americ   Pacific             East     and                                         Oncolo       Immun     Women Metabol Genetic
                                a                          and     Central                                        gy          ology      's      ic   Disorde
                                                          Africa   Americ                                                              Health Disorde    rs
                                                                     a                                                                           rs



         Note: Deals include all announced pharmaceuticals & healthcare deals             Note: Deals include all announced pharmaceuticals & healthcare deals
         from 2006 onwards, GlobalData                                                    from 2006 onwards, GlobalData




Synageva BioPharma Corp. - Pharmaceuticals & Healthcare -                                                                                      Reference Code: GDPH137372D
Deals and Alliances Profile
Source : www.globalcompanyintelligence.com                                                                                                                                Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 3
          List of Figures ................................................................................................................................................................................. 3
       Synageva BioPharma Corp., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ..................................................... 4
       Synageva BioPharma Corp., Pharmaceuticals & Healthcare Deals By Type, 2007 to YTD 2013 ...................................................... 5
       Synageva BioPharma Corp., Pharmaceuticals & Healthcare, Deals By Region, 2007 to YTD 2013 ................................................. 6
       Synageva BioPharma Corp., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2007 to YTD 2013 ....................................... 7
       Synageva BioPharma Corp., Pharmaceuticals & Healthcare, Deals Summary, 2007 to YTD 2013................................................... 8
       Synageva BioPharma Corp., Pharmaceuticals & Healthcare, Deal Details ........................................................................................ 9
          Venture Financing........................................................................................................................................................................... 9
             Synageva Biopharma Secures US$25 Million In Equity Financing ............................................................................................. 9
             Synageva BioPharma Secures US$45 Million In Financing ...................................................................................................... 11
          Partnerships.................................................................................................................................................................................. 13
             Synageva BioPharma Extends Co-Development Agreement With Mitsubishi Tanabe Pharma ................................................ 13
             Synageva BioPharma Enters Into Research Agreement With Mitsubishi Tanabe Pharma ....................................................... 14
             Morphotek Enters Into An Agreement With Synageva BioPharma ........................................................................................... 15
          Merger .......................................................................................................................................................................................... 16
             Synageva BioPharma Completes Merger With Trimeris ........................................................................................................... 16
          Equity Offering .............................................................................................................................................................................. 18
             Synageva BioPharma Completes Public Offering Of Common Stock For US$118 Million........................................................ 18
             Synageva BioPharma Completes Public Offering Of Common Stock For US$115 Million........................................................ 20
             Synageva BioPharma Completes Public Offering Of Common Stock For US$90 Million.......................................................... 22
       Synageva BioPharma Corp. - Key Competitors ............................................................................................................................... 24
       Key Employees ................................................................................................................................................................................ 25
       Locations And Subsidiaries .............................................................................................................................................................. 26
          Head Office ................................................................................................................................................................................... 26
       Recent Developments ...................................................................................................................................................................... 27
          Financial Announcements............................................................................................................................................................. 27
             May 07, 2013: Synageva Reports Revenue Of $5.1m In Q1 2013 ........................................................................................... 27
             Mar 11, 2013: Synageva Reports Revenue Of $15m In 2012 ................................................................................................... 28
             Nov 06, 2012: Synageva BioPharma Reports Revenue Of $5.4m In Q3 2012 ......................................................................... 29
             Aug 03, 2012: Synageva BioPharma Reports Revenue Of $2.2m In Q2 2012 .......
				
DOCUMENT INFO
Description: Synageva BioPharma Corp. (Synageva) is a biopharmaceutical company. The company discovers, develops and delivers medicines for patients with rare disease and unmet medical need. Its programs include SBC-102, SBC-103, SBC-104, SBC-105 and SBC-106. Synageva’s SBC-102 is an enzyme replacement therapy for lysosomal acid lipase deficiency, a lysosomal storage disorder. The company’s SBC-102 contains glycan structures that are specifically recognized and internalized by specific receptors into key target cells. It has received orphan drug designations in both the US and EU in 2010 for SBC-102 for LAL deficiency. The company’s expression platform is an integrated approach using recombinant DNA technology for the creation, optimization and commercial production of protein therapeutics. Synageva is headquartered in Lexington, Massachusetts, the US. Synageva BioPharma Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value
BUY THIS DOCUMENT NOW PRICE: $250 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.